熱門資訊> 正文
Sarepta Therapeutics再融资7亿美元可转换票据
2025-08-21 19:15
- Sarepta Therapeutics (NASDAQ:SRPT) reached agreements with select noteholders to exchange about $700M of its 1.25% convertible notes due 2027 for $602M of new 4.875% notes due 2030, up to 6.7M shares of common stock, and $123M in cash.
- The new notes carry a conversion rate of 16.6667 shares per $1,000 principal amount of the notes—equivalent to a conversion price of $60 per share, a 191% premium to the stock’s Aug. 20 closing price of $20.58. Sarepta also signed a deal with J. Wood Capital Advisors for a private placement of up to 1.4M shares.
- SRPT -2.33%.
More on Sarepta Therapeutics
- Sarepta Therapeutics: Beaten Down, But Not Out
- Sarepta: Despite Restructuring, Downgrading To Sell After Latest Developments
- Strategic Restructure and ELEVIDYS Label Update Call
- Sarepta sells Arrowhead stock, activates $100M milestone payment
- Biotech sector slips amid reported return of ousted FDA official
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。